{"id":"placebo-matching-with-metformin-ir","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo matching refers to a dummy formulation designed to be indistinguishable from the active drug in appearance and administration schedule, used to preserve trial blinding. The active comparator, Metformin IR, is a biguanide that decreases hepatic gluconeogenesis and enhances peripheral glucose uptake by activating AMP-activated protein kinase (AMPK). This combination is typical in randomized controlled trials evaluating new antidiabetic agents against the metformin standard of care.","oneSentence":"This is a placebo-matched formulation used in clinical trials to maintain blinding while comparing against Metformin IR (immediate-release), which reduces hepatic glucose production and improves insulin sensitivity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:01:10.794Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Used as control arm in clinical trials for type 2 diabetes or related metabolic disorders"}]},"trialDetails":[{"nctId":"NCT06042855","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2023-09-05","conditions":"Covid19","enrollment":3214},{"nctId":"NCT04885530","phase":"PHASE3","title":"ACTIV-6: COVID-19 Study of Repurposed Medications","status":"COMPLETED","sponsor":"Susanna Naggie, MD","startDate":"2021-06-08","conditions":"Covid19","enrollment":10956},{"nctId":"NCT03507413","phase":"PHASE2, PHASE3","title":"Metformin Therapy in Non-diabetic AAA Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Vienna","startDate":"2018-09-26","conditions":"Abdominal Aortic Aneurysm","enrollment":170},{"nctId":"NCT01864174","phase":"PHASE4","title":"Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-06-20","conditions":"Type 2 Diabetes Mellitus","enrollment":1736},{"nctId":"NCT02791490","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-06-16","conditions":"Type 2 Diabetes Mellitus","enrollment":458},{"nctId":"NCT02492763","phase":"PHASE2","title":"A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-27","conditions":"Type II Diabetes Mellitus","enrollment":176},{"nctId":"NCT02526524","phase":"PHASE2","title":"Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM","status":"COMPLETED","sponsor":"Elcelyx Therapeutics, Inc.","startDate":"2015-09","conditions":"Type 2 Diabetes Mellitus","enrollment":571},{"nctId":"NCT03061981","phase":"PHASE1","title":"A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2017-03-29","conditions":"Diabetes Mellitus, Type 2","enrollment":60},{"nctId":"NCT01204775","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-06","conditions":"Type 2 Diabetes","enrollment":26},{"nctId":"NCT01434186","phase":"PHASE3","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-05","conditions":"Diabetes Mellitus, Type 2","enrollment":32},{"nctId":"NCT01646320","phase":"PHASE3","title":"Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-09","conditions":"Type 2 Diabetes","enrollment":320},{"nctId":"NCT01619059","phase":"PHASE3","title":"Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-06","conditions":"Type 2 Diabetes","enrollment":315},{"nctId":"NCT01106677","phase":"PHASE3","title":"The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2010-05","conditions":"Diabetes Mellitus, Type 2","enrollment":1284}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo matching with Metformin IR","genericName":"Placebo matching with Metformin IR","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo-matched formulation used in clinical trials to maintain blinding while comparing against Metformin IR (immediate-release), which reduces hepatic glucose production and improves insulin sensitivity. Used for Used as control arm in clinical trials for type 2 diabetes or related metabolic disorders.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}